This 3-year extension study aims at making available the treatment with secukinumab in prefilled syringes (PFS) to patients with ankylosing spondylitis who took part in phase III study CAIN457F2305, defined as "core study", as well as to generate additional data on the sustainability of clinical benefits, safety and tolerability during long-term administration of secukinumab.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01863732?cond=%22Arthritis%22&lup_s=01/29/2014&lup_d=30
